Scynexis (SCYX) Non Operating Income (2013 - 2026)
Scynexis' (SCYX) quarterly Non Operating Income came in at -$4.4 million in Q1 2026, down 235.45% YoY from $3.2 million in Q1 2025, and down 351.01% on a QoQ basis from $1.7 million in Q4 2025.
Scynexis (SCYX) Non Operating Income (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has 14 years of Non Operating Income data on file, last reported at -$4.4 million in Q1 2026.
- Quarterly Non Operating Income fell 235.45% year-over-year to -$4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$133000.0 (down 101.52% YoY) and the FY2025 annual result came in at $7.5 million, down 53.29% from the prior year.
- Non Operating Income fell to -$4.4 million in Q1 2026, from $1.7 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $10.4 million in Q1 2024 to a low of -$23.2 million in Q1 2023.
- A 5-year average of $1.9 million and a median of $3.6 million in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income jumped 583.7% — and 2023, when it slumped 341.93%.
- Tracing SCYX's Non Operating Income over 5 years: stood at $8.1 million in 2022, then slumped by 55.08% to $3.6 million in 2023, then advanced by 0.72% to $3.6 million in 2024, then plunged by 52.32% to $1.7 million in 2025, then tumbled by 351.01% to -$4.4 million in 2026.
- The last three Non Operating Income figures came in at -$4.4 million (Q1 2026), $1.7 million (Q4 2025), and -$186000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -224.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 5.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 41.90 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 10.70 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Scynexis | 60.95 Mn | -53.74 Mn | - | 15.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.17 Mn |
| Mar 31, 2026 | -4.36 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | -186,000.00 |
| Jun 30, 2025 | 2.68 Mn |
| Mar 31, 2025 | 3.22 Mn |
| Dec 31, 2024 | 3.64 Mn |
| Sep 30, 2024 | 7.12 Mn |
| Jun 30, 2024 | -5.22 Mn |
| Mar 31, 2024 | 10.45 Mn |
| Dec 31, 2023 | 3.62 Mn |
| Sep 30, 2023 | 8.34 Mn |
| Jun 30, 2023 | 5.75 Mn |
| Mar 31, 2023 | -23.19 Mn |
| Dec 31, 2022 | 8.05 Mn |
| Sep 30, 2022 | -7.78 Mn |
| Jun 30, 2022 | 8.39 Mn |
| Mar 31, 2022 | 9.59 Mn |
| Dec 31, 2021 | -6.95 Mn |
| Sep 30, 2021 | 18.79 Mn |